Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
BNT162b2 mRNA vaccine
Omicron
SARS-CoV-2
binding antibodies
neutralizing antibodies
surrogate virus neutralization tests
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
26 09 2023
26 09 2023
Historique:
received:
11
12
2022
accepted:
27
03
2023
medline:
21
8
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
To assess the long-term humoral immunity induced by booster administration, as well as the ability of binding antibody and surrogate virus neutralization tests (sVNT) to predict neutralizing antibodies (NAbs) against the SARS-CoV-2 Omicron variant. A total of 269 sera samples were analyzed from 64 healthcare workers who had received a homologous booster dose of BNT162b2. Neutralizing antibodies assessed by sVNT and anti-RBD IgG measured with the sCOVG assay (Siemens Healthineers While Wild-type sVNT percentage of inhibition (POI) remained above 98.6% throughout the follow-up period after booster administration, anti-RBD IgG and NAbs assessed by Omicron BA.1 pVNT showed respectively a 3.4-fold and 13.3-fold decrease after 6 months compared to the peak reached at day 14. NAbs assessed by Omicron sVNT followed a steady decline until reaching a POI of 53.4%. Anti-RBD IgG and Omicron sVNT assays were strongly correlated (r=0.90) and performed similarly to predict the presence of neutralizing antibodies with Omicron pVNT (area under the ROC: 0.82 for both assays). In addition, new adapted cut-off values of anti-RBD IgG (>1,276 BAU/mL) and Omicron sVNT (POI>46.6%) were found to be better predictors of neutralizing activity. This study showed a significant drop in humoral immunity 6 months after booster administration. Anti-RBD IgG and Omicron sVNT assays were highly correlated and could predict neutralizing activity with moderate performance.
Identifiants
pubmed: 37078220
pii: cclm-2022-1258
doi: 10.1515/cclm-2022-1258
doi:
Substances chimiques
Antibodies, Neutralizing
0
BNT162 Vaccine
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1875-1885Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Karim, SSA, Karim, QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126–8. https://doi.org/10.1016/s0140-6736(21)02758-6 .
doi: 10.1016/s0140-6736(21)02758-6
Planas, D, Saunders, N, Maes, P, Guivel-Benhassine, F, Planchais, C, Buchrieser, J, et al.. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2022;602:671–5. https://doi.org/10.1038/s41586-021-04389-z .
doi: 10.1038/s41586-021-04389-z
Dejnirattisai, W, Huo, J, Zhou, D, Zahradnik, J, Supasa, P, Liu, C, et al.. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 2022;185:467–84 e15. https://doi.org/10.1016/j.cell.2021.12.046 .
doi: 10.1016/j.cell.2021.12.046
Cele, S, Jackson, L, Khoury, DS, Khan, K, Moyo-Gwete, T, Tegally, H, et al.. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022;602:654–6. https://doi.org/10.1038/s41586-021-04387-1 .
doi: 10.1038/s41586-021-04387-1
Cheng, SMS, Mok, CKP, Leung, YWY, Ng, SS, Chan, KCK, Ko, FW, et al.. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med 2022;28:486–9. https://doi.org/10.1038/s41591-022-01704-7 .
doi: 10.1038/s41591-022-01704-7
Gruell, H, Vanshylla, K, Tober-Lau, P, Hillus, D, Schommers, P, Lehmann, C, et al.. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med 2022;28:477–80. https://doi.org/10.1038/s41591-021-01676-0 .
doi: 10.1038/s41591-021-01676-0
Cao, Y, Yisimayi, A, Jian, F, Song, W, Xiao, T, Wang, L, et al.. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022;608:593–602. https://doi.org/10.1038/s41586-022-04980-y .
doi: 10.1038/s41586-022-04980-y
Hachmann, NP, Miller, J, Collier, AY, Ventura, JD, Yu, J, Rowe, M, et al.. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:86–8. https://doi.org/10.1056/nejmc2206576 .
doi: 10.1056/nejmc2206576
Wang, Q, Guo, Y, Iketani, S, Nair, MS, Li, Z, Mohri, H, et al.. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022;608:603–8. https://doi.org/10.1038/s41586-022-05053-w .
doi: 10.1038/s41586-022-05053-w
Hachmann, NP, Miller, J, Collier, AY, Barouch, DH. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.4.6. N Engl J Med 2022;387:1904–6. https://doi.org/10.1056/nejmc2212117 .
doi: 10.1056/nejmc2212117
Powell, AA, Kirsebom, F, Stowe, J, McOwat, K, Saliba, V, Ramsay, ME, et al.. Effectiveness of BNT162b2 against COVID-19 in adolescents. Lancet Infect Dis 2022;22:581–3. https://doi.org/10.1016/s1473-3099(22)00177-3 .
doi: 10.1016/s1473-3099(22)00177-3
Andrews, N, Stowe, J, Kirsebom, F, Toffa, S, Rickeard, T, Gallagher, E, et al.. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532–46. https://doi.org/10.1056/nejmoa2119451 .
doi: 10.1056/nejmoa2119451
Bayart, JL, Douxfils, J, Gillot, C, David, C, Mullier, F, Elsen, M, et al.. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. Vaccines (Basel) 2021;9:1092. https://doi.org/10.3390/vaccines9101092 .
doi: 10.3390/vaccines9101092
Feikin, DR, Higdon, MM, Abu-Raddad, LJ, Andrews, N, Araos, R, Goldberg, Y, et al.. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022;399:924–44. https://doi.org/10.1016/s0140-6736(22)00152-0 .
doi: 10.1016/s0140-6736(22)00152-0
Hall, V, Foulkes, S, Insalata, F, Kirwan, P, Saei, A, Atti, A, et al.. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022;386:1207–20. https://doi.org/10.1056/nejmoa2118691 .
doi: 10.1056/nejmoa2118691
Chemaitelly, H, Ayoub, HH, AlMukdad, S, Coyle, P, Tang, P, Yassine, HM, et al.. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun 2022;13:3082. https://doi.org/10.1038/s41467-022-30895-3 .
doi: 10.1038/s41467-022-30895-3
Schmidt, F, Muecksch, F, Weisblum, Y, Da Silva, J, Bednarski, E, Cho, A, et al.. Plasma neutralization of the SARS-CoV-2 Omicron variant. N Engl J Med 2022;386:599–601. https://doi.org/10.1056/nejmc2119641 .
doi: 10.1056/nejmc2119641
Lassauniere, R, Polacek, C, Frische, A, Boding, L, Saekmose, SG, Rasmussen, M, et al.. Neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) 1 to 18 weeks after the second and third doses of the BNT162b2 mRNA vaccine. JAMA Netw Open 2022;5:e2212073. https://doi.org/10.1001/jamanetworkopen.2022.12073 .
doi: 10.1001/jamanetworkopen.2022.12073
Buchan, SA, Chung, H, Brown, KA, Austin, PC, Fell, DB, Gubbay, JB, et al.. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. JAMA Netw Open 2022;5:e2232760. https://doi.org/10.1001/jamanetworkopen.2022.32760 .
doi: 10.1001/jamanetworkopen.2022.32760
Khoury, DS, Cromer, D, Reynaldi, A, Schlub, TE, Wheatley, AK, Juno, JA, et al.. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–11. https://doi.org/10.1038/s41591-021-01377-8 .
doi: 10.1038/s41591-021-01377-8
Earle, KA, Ambrosino, DM, Fiore-Gartland, A, Goldblatt, D, Gilbert, PB, Siber, GR, et al.. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423–8. https://doi.org/10.1016/j.vaccine.2021.05.063 .
doi: 10.1016/j.vaccine.2021.05.063
Cromer, D, Steain, M, Reynaldi, A, Schlub, TE, Wheatley, AK, Juno, JA, et al.. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 2022;3:e52–61. https://doi.org/10.1016/s2666-5247(21)00267-6 .
doi: 10.1016/s2666-5247(21)00267-6
Yang, Y, Du, L. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. Signal Transduct Targeted Ther 2021;6:95. https://doi.org/10.1038/s41392-021-00523-5 .
doi: 10.1038/s41392-021-00523-5
Favresse, J, Gillot, C, Bayart, JL, David, C, Simon, G, Wauthier, L, et al.. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. J Med Virol 2023;95:e28164. https://doi.org/10.1002/jmv.28164 .
doi: 10.1002/jmv.28164
Dimeglio, C, Migueres, M, Bouzid, N, Chapuy-Regaud, S, Gernigon, C, Da-Silva, I, et al.. Antibody titers and protection against Omicron (BA.1 and BA.2) SARS-CoV-2 infection. Vaccines (Basel) 2022;10. https://doi.org/10.3390/vaccines10091548 .
doi: 10.3390/vaccines10091548
Dimeglio, C, Tremeaux, P, Herin, F, Da-Silva, I, Porcheron, M, Martin-Blondel, G, et al.. Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population. J Infect 2022;85:702–69. https://doi.org/10.1016/j.jinf.2022.08.040 .
doi: 10.1016/j.jinf.2022.08.040
World Health Organization . Interim statement on booster doses for COVID-19 vaccination 2021 . Available from: https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination–-update-22-december-2021 .
Monge, S, Rojas-Benedicto, A, Olmedo, C, Mazagatos, C, Jose Sierra, M, Limia, A, et al.. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis 2022;22:1313–20. https://doi.org/10.1016/s1473-3099(22)00292-4 .
doi: 10.1016/s1473-3099(22)00292-4
Cheng, H, Peng, Z, Si, S, Alifu, X, Zhou, H, Chi, P, et al.. Immunogenicity and safety of homologous and heterologous prime-boost immunization with COVID-19 vaccine: systematic review and meta-analysis. Vaccines (Basel) 2022;10:798. https://doi.org/10.3390/vaccines10050798 .
doi: 10.3390/vaccines10050798
Gilboa, M, Regev-Yochay, G, Mandelboim, M, Indenbaum, V, Asraf, K, Fluss, R, et al.. Durability of immune response after COVID-19 booster vaccination and association with COVID-19 Omicron infection. JAMA Netw Open 2022;5:e2231778. https://doi.org/10.1001/jamanetworkopen.2022.31778 .
doi: 10.1001/jamanetworkopen.2022.31778
Douxfils, J, Gillot, C, Mullier, F, Favresse, J. Post-SARS-CoV-2 vaccination specific antibody decrease – thresholds for determining seroprevalence and seroneutralization differ. J Infect 2021;83:e4–5. https://doi.org/10.1016/j.jinf.2021.08.023 .
doi: 10.1016/j.jinf.2021.08.023
Gillot, C, Favresse, J, Maloteau, V, Dogne, JM, Douxfils, J. Identification of SARS-CoV-2 neutralizing antibody with pseudotyped virus-based test on HEK-293T hACE2 cells. Bio Protoc 2022;12:e4377. https://doi.org/10.21769/bioprotoc.4377 .
doi: 10.21769/bioprotoc.4377
Favresse, J, Eucher, C, Elsen, M, Tre-Hardy, M, Dogne, JM, Douxfils, J. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem 2020;66:1104–6. https://doi.org/10.1093/clinchem/hvaa131 .
doi: 10.1093/clinchem/hvaa131
Cruz-Cardenas, JA, Gutierrez, M, Lopez-Arredondo, A, Castaneda-Delgado, JE, Rojas-Martinez, A, Nakamura, Y, et al.. A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept. Sci Rep 2022;12:17966. https://doi.org/10.1038/s41598-022-22921-7 .
doi: 10.1038/s41598-022-22921-7
Kinsley, R, Pronost, S, De Bock, M, Temperton, N, Daly, JM, Paillot, R, et al.. Evaluation of a pseudotyped virus neutralisation test for the measurement of equine influenza virus-neutralising antibody responses induced by vaccination and infection. Vaccines (Basel) 2020;8:466. https://doi.org/10.3390/vaccines8030466 .
doi: 10.3390/vaccines8030466
Nie, J, Li, Q, Wu, J, Zhao, C, Hao, H, Liu, H, et al.. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 2020;15:3699–715. https://doi.org/10.1038/s41596-020-0394-5 .
doi: 10.1038/s41596-020-0394-5
Favresse, J, Douxfils, J, Henry, B, Lippi, G, Plebani, M. Clinical Chemistry and Laboratory Medicine celebrates 60 years – narrative review devoted to the contribution of the journal to the diagnosis of SARS-CoV-2. Clin Chem Lab Med 2022;61:811–21.
Assawakosri, S, Kanokudom, S, Suntronwong, N, Auphimai, C, Nilyanimit, P, Vichaiwattana, P, et al.. Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis 2022;226:1372–81. https://doi.org/10.1093/infdis/jiac092 .
doi: 10.1093/infdis/jiac092
Lee, B, Ko, JH, Park, J, Moon, HW, Baek, JY, Jung, S, et al.. Estimating the neutralizing effect and titer correlation of semi-quantitative anti-SARS-CoV-2 antibody immunoassays. Front Cell Infect Microbiol 2022;12:822599. https://doi.org/10.3389/fcimb.2022.822599 .
doi: 10.3389/fcimb.2022.822599
Valcourt, EJ, Manguiat, K, Robinson, A, Chen, JC, Dimitrova, K, Philipson, C, et al.. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis 2021;99:115294. https://doi.org/10.1016/j.diagmicrobio.2020.115294 .
doi: 10.1016/j.diagmicrobio.2020.115294
Alsoussi, WB, Turner, JS, Case, JB, Zhao, H, Schmitz, AJ, Zhou, JQ, et al.. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. J Immunol 2020;205:915–22. https://doi.org/10.4049/jimmunol.2000583 .
doi: 10.4049/jimmunol.2000583
Chi, X, Guo, Y, Zhang, G, Sun, H, Zhang, J, Li, M, et al.. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. Signal Transduct Targeted Ther 2022;7:139. https://doi.org/10.1038/s41392-022-00987-z .
doi: 10.1038/s41392-022-00987-z
Gattinger, P, Niespodziana, K, Stiasny, K, Sahanic, S, Tulaeva, I, Borochova, K, et al.. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes. Allergy 2022;77:230–42. https://doi.org/10.1111/all.15066 .
doi: 10.1111/all.15066
Ramos, A, Cardoso, MJ, Ribeiro, L, Guimaraes, JT. Assessing SARS-CoV-2 neutralizing antibodies after BNT162b2 vaccination and their correlation with SARS-CoV-2 IgG anti-S1, anti-RBD and anti-S2 serological titers. Diagnostics (Basel) 2022;12:205. https://doi.org/10.3390/diagnostics12010205 .
doi: 10.3390/diagnostics12010205
Kitagawa, Y, Imai, K, Matsuoka, M, Fukada, A, Kubota, K, Sato, M, et al.. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test. J Med Virol 2022;94:335–41. https://doi.org/10.1002/jmv.27338 .
doi: 10.1002/jmv.27338
Nam, M, Seo, JD, Moon, HW, Kim, H, Hur, M, Yun, YM. Evaluation of humoral immune response after SARS-CoV-2 vaccination using two binding antibody assays and a neutralizing antibody assay. Microbiol Spectr 2021;9:e0120221. https://doi.org/10.1128/spectrum.01202-21 .
doi: 10.1128/spectrum.01202-21
Kohmer, N, Rabenau, HF, Ciesek, S, Kramer, BK, Gottmann, U, Keller, C, et al.. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. Nephrol Dial Transplant 2022;37:1132–9. https://doi.org/10.1093/ndt/gfac018 .
doi: 10.1093/ndt/gfac018
Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, et al.. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032–40. https://doi.org/10.1038/s41591-021-01540-1 .
doi: 10.1038/s41591-021-01540-1
Chapuy-Regaud, S, Miedouge, M, Abravanel, F, Da Silva, I, Porcheron, M, Fillaux, J, et al.. Evaluation of three quantitative Anti-SARS-CoV-2 antibody immunoassays. Microbiol Spectr 2021;9:e0137621. https://doi.org/10.1128/spectrum.01376-21 .
doi: 10.1128/spectrum.01376-21
Resman Rus, K, Korva, M, Knap, N, Avsic Zupanc, T, Poljak, M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol 2021;139:104820. https://doi.org/10.1016/j.jcv.2021.104820 .
doi: 10.1016/j.jcv.2021.104820
Dimeglio, C, Herin, F, Martin-Blondel, G, Miedouge, M, Izopet, J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect 2022;84:248–88. https://doi.org/10.1016/j.jinf.2021.09.013 .
doi: 10.1016/j.jinf.2021.09.013
Springer, DN, Perkmann, T, Jani, CM, Mucher, P, Pruger, K, Marculescu, R, et al.. Reduced sensitivity of commercial spike-specific antibody assays after primary infection with the SARS-CoV-2 omicron variant. Microbiol Spectr 2022;10:e0212922. https://doi.org/10.1128/spectrum.02129-22 .
doi: 10.1128/spectrum.02129-22
McCallum, M, Czudnochowski, N, Rosen, LE, Zepeda, SK, Bowen, JE, Walls, AC, et al.. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 2022;375:864–8. https://doi.org/10.1126/science.abn8652 .
doi: 10.1126/science.abn8652
Suntronwong, N, Assawakosri, S, Kanokudom, S, Yorsaeng, R, Auphimai, C, Thongmee, T, et al.. Strong correlations between the binding antibodies against Wild-type and neutralizing antibodies against Omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third-dose) vaccination. Diagnostics (Basel) 2022;12:1781. https://doi.org/10.3390/diagnostics12081781 .
doi: 10.3390/diagnostics12081781
Bergwerk, M, Gonen, T, Lustig, Y, Amit, S, Lipsitch, M, Cohen, C, et al.. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474–84. https://doi.org/10.1056/nejmoa2109072 .
doi: 10.1056/nejmoa2109072
McMahan, K, Yu, J, Mercado, NB, Loos, C, Tostanoski, LH, Chandrashekar, A, et al.. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630–4. https://doi.org/10.1038/s41586-020-03041-6 .
doi: 10.1038/s41586-020-03041-6
Saker, K, Escuret, V, Pitiot, V, Massardier-Pilonchery, A, Paul, S, Mokdad, B, et al.. Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated health care workers. J Clin Microbiol 2022;60:e0174621. https://doi.org/10.1128/jcm.01746-21 .
doi: 10.1128/jcm.01746-21
Giavarina, D, Carta, M. Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization. Diagnosis (Berl) 2021;9:274–9. https://doi.org/10.1515/dx-2021-0126 .
doi: 10.1515/dx-2021-0126
Zhuo, R, Charlton, C, Plitt, S, Thompson, LA, Braun, S, Day, J, et al.. Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assays. J Clin Virol 2022;156:105292. https://doi.org/10.1016/j.jcv.2022.105292 .
doi: 10.1016/j.jcv.2022.105292
Tuekprakhon, A, Nutalai, R, Dijokaite-Guraliuc, A, Zhou, D, Ginn, HM, Selvaraj, M, et al.. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 2022;185:2422–33e13. https://doi.org/10.1016/j.cell.2022.06.005 .
doi: 10.1016/j.cell.2022.06.005
Khan, K, Karim, F, Ganga, Y, Bernstein, M, Jule, Z, Reedoy, K, et al.. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat Commun 2022;13:4686. https://doi.org/10.1038/s41467-022-32396-9 .
doi: 10.1038/s41467-022-32396-9